IL17A and metabolic dysfunction-associated steatotic liver disease: The results showed (Figure 3D) that the relevant components in treating NAFLD were mainly associated with the AGE-RAGE signaling pathway in diabetic complications, HIF-1 signaling pathway, and IL-17 signaling pathway.